---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Care management intervention strategies"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Care management intervention strategies. Topics: Delphi consensus: counseling before and after APOL1 testing, Delphi consensus: barriers to testing, Delphi consensus: disease awareness and community education, KDIGO Controversies Conference: requirements for operating APOL1 testing and community engagement, and 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Delphi consensus: counseling before and after APOL1 testing

> “Patients should have a clear understanding of the purpose of the APOL1 test and the potential implications of the result before the test is taken”
> “When health care professionals discuss APOL1 testing with their patients, they should be honest and transparent about the current understanding of APOL1, take time to discuss APOL1 with patients, listen to their concerns, answer questions, and provide information sources that are balanced, easy to use and understand, and reliable”
> “After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:”
> “Encourage the patient to participate in clinical trials for which they are eligible”
> “Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)”
> “There is no established best practice for counseling patients about APOL1 testing; further research is required to define best practice”
> “Nephrology trainees need to be educated to be able to confidently deliver effective counseling to patients about APOL1 testing”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-2"></a>

### Delphi consensus: barriers to testing

> “Clinicians’ lack of confidence in communicating the findings from APOL1 testing to patients in a clear and effective way that minimizes patient confusion and misunderstanding is a major barrier to APOL1 testing in patients with nephropathy”
> “Low levels of trust in the medical establishment could be a barrier to APOL1 testing in the Black community”
> “The lack of specific treatment and concerns regarding insurance reimbursement for genetic testing and potential discrimination on the basis of APOL1 genotype (e.g., life insurance, health insurance, job security) may be barriers to physicians educating patients about APOL1-associated nephropathy”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-3"></a>

### Delphi consensus: disease awareness and community education

> “There are low levels of awareness of APOL1-associated nephropathy in the Black community”
> “Nephrologists, primary care providers, nurses, community leaders, and patient networks all have an important role to play in educating Black patients with nephropathy about the APOL1 gene”
> “To improve awareness of APOL1 among the patient community, health care professionals should work with community leaders and community groups and should provide education in a setting that is familiar and comfortable for patients”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-4"></a>

### KDIGO Controversies Conference: requirements for operating APOL1 testing and community engagement

> “For operationalizing genetic testing, the following are necessary: a validated test in a registered laboratory with appropriately trained staff; pre- and post-testing counseling; availability of co-designed educational material tailored to levels of health literacy; and a process for early surveillance and intervention, including in children. In high prevalence populations, community leaders, content experts, and faith leaders should be engaged to facilitate community education initiatives.”
> “Authentic community engagement is critical in designing and implementing APOL1 prevalence and research studies, testing in clinical care, as well as communicating how findings inform recommendations.”
> “Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-5"></a>

### KDIGO Controversies Conference: principles for deciding on APOL1 testing

> “Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.”
> “CKD care and screening are available AND APOL1 test results could change management (e.g., an effective treatment for APOL1 is available OR results could lead to increased surveillance for CKD OR results would inform risk/benefit evaluation in decision-making about living kidney donation).”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-6"></a>

### KDIGO Controversies Conference: community outreach for clinical trial participation

> “To raise awareness about CKD and APOL1 kidney disease as well as encourage participation in clinical trials, community outreach is required to develop, strengthen, and sustain relationships with trusted community leaders and partners.”
> “As the understanding of and treatments for APOL1 kidney disease are further developed, engagement and education of communities and health care professionals, including those in primary care, will be key in improving patient health in all regions affected.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-7"></a>

### Genetic counseling and surveillance after a high-risk result

> “All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype. When individuals are noted to have a high-risk genotype, physicians may consider more frequent screening for reduced GFR and proteinuria to identify AMKD at an early stage.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.2.4-8"></a>

### KDIGO 2024 CKD guideline: genetic testing and counseling

> “Genetic testing is emerging as a valuable component for evaluation of cause.”
> “Access to genetic counseling and medical genetics is important for psychosocial support, appropriate use of genetic testing, and to limit costs.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.4-9"></a>

### Manufacturer-sponsored no-cost APOL1 testing program

> “Through this program, Labcorp will perform testing using the lab-developed APOL1 Genotype Test. Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”
> “No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “Labcorp and Vertex Pharmaceuticals reserve the right to rescind, revoke or amend the program for any reason without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.2.4-10"></a>

### Returning APOL1 results to patients with hypertension: randomized trial

> “This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018.”
> “At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes (6 [18] vs 3 [18] mm Hg; P = .004) and controls (6 [18] vs 3 [19] mm Hg; P = .01).”

Source: [Nadkarni et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8897752/)

<a id="topic-2.2.2.4-11"></a>

### Manufacturer disease awareness campaign

> “an educational initiative aimed at raising awareness of APOL1-mediated kidney disease (AMKD), highlighting the importance of early diagnosis and genetic testing.”
> “Diagnosis depends on a urine test to detect proteinuria, and blood tests to detect reduced kidney function and the two APOL1 risk variants.”

Source: [Vertex Pharmaceuticals press release, AMKD awareness partnership (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-partnership-basketball-hall-famer-alonzo)

<a id="topic-2.2.2.4-12"></a>

### Transplant center APOL1 testing policies: Delphi panel

> “Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.”

Source: [McIntosh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020447/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
